Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis

Bacterial Vaginoses Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled Study to Confirm the Efficacy and Safety of Multi- Gyn ActiGel Plus for Treatment of Bacterial Vaginosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04807842
• Other study ID #: MGAP BV 001
• Status: Recruiting
• Phase: N/A
• Start date: June 11, 2021
• Est. completion date: December 1, 2024

Study information

• Verified date: October 2023
• Source: Karo Pharma AB
• Contact: Diana Zeneli, MD
• Phone: 0031614706949
• Email: diana.pasho[@]karopharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled clinical investigation. The objective of the study is to confirm the efficacy of Multi-Gyn ActiGel Plus to treat BV as compared to a placebo control.

Treatment arm 1: Multi-Gyn ActiGel Plus Treatment arm 2: placebo gel Both the Multi-Gyn ActiGel Plus and the placebo will be applied twice a day for 7 consecutive days. Visit 2 will be performed at 3 weeks after start of treatment A phone call will take place, at 5 weeks after start of treatment for subject with clinical cure at Visit 2. The total duration per subject is estimated 5 weeks and the total study duration is 13 months. Sample size is 100 subjects per treatment arm.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 1, 2024
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women diagnosed with BV (3 out of 4 Amsel criteria positive, with at least presence of clue cells (>20%))

• Women of childbearing potential

• Aged >18 years

• Signed written informed consent form

• Willing to comply to the follow-up schedule

Exclusion Criteria:

• Current clinically manifest of sexually transmitted gynecologically infection, genital tract infection, vulvovaginal candidosis or aerobic vaginitis (incl. clinical obvious gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis, urethritis, salpingitis)

• Presence of Trichomonas and/or Candida Albicans in vaginal smear during examination of the smears for Amstel criteria (clue cells detection)

• Current genital malignancies

• Chemotherapy for any reason in last 6 months

• Radiotherapy in the genitourinary system in the last 12 months

• Use of antibiotics for any reason in the last 14 days

• Use of intravaginal devices during the investigation or in the last 14 days

• Pregnancy or currently attempting to conceive

• Lactation

• Use of other treatment for vaginal conditions during the course of the clinical investigation

• Known allergies to ingredients of the product

• Concomitant medication for treatment of vaginal infections, or other use of intravaginal medication during the course of the clinical investigation

Related Conditions & MeSH terms

• Bacterial Vaginoses
• Vaginal Diseases
• Vaginosis, Bacterial

Intervention

Device:
• vaginal gel
The placebo gel is a non-buffered gel. The active device is an acidic gel.

Locations

Country	Name	City	State
Germany	Praxis Dr. Peters	Hamburg

Sponsors (2)

Lead Sponsor	Collaborator
BioClin BV	Avania

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical cure rate of BV at 3 weeks after start of treatment (end-of treatment visit; Visit 2).	Clinical cure is defined based on the following Amsel criteria: presence of clue cells <20% of the total epithelial cells on microscopic examination of the saline wet mount; resolution of the abnormal vaginal discharge, and; a negative whiff test	3 weeks
Secondary	Microbiological cure rate (based on Nugent score <4) at Visit 2	The secondary objective of the study is to confirm the secondary efficacy of the product.	3 weeks